

IN THE CLAIMS

Claims 1-2 (canceled)

3. (currently amended) An isolated complex comprising at least one ubiquitin or a derivative thereof, and a protein; wherein said protein is selected from the group consisting of aprataxin, ~~tau~~, SLP, HMG17, PinX1, CIR, ~~Cullin-3~~, HMGN3, HSPC144 and CDC6 and fragments and derivatives thereof, wherein said fragments and derivatives thereof comprise polypeptides of at least 10 amino acids having at least 60% sequence similarity to sequences within their corresponding proteins; and said complex is formed via N-end rule ubiquitylation.

4. (previously presented) The complex of claim 1, wherein said complex is immobilized on a support and/or linked to a label.

5. (currently amended) A method for producing a complex comprising at least one ubiquitin or a derivative thereof, and a protein; wherein said protein is selected from the group consisting of aprataxin, ~~tau~~, SLP, HMG17, PinX1, CIR, ~~Cullin-3~~, HMGN3, HSPC144 and CDC6 and fragments and derivatives thereof, wherein said fragments and derivatives thereof comprise polypeptides of at least 10 amino acids having at least 60% sequence similarity to sequences within their corresponding proteins, comprising:

- a) forming a mixture comprising a vector containing a clone coding for said protein, an *in vitro* transcription/translation system, an N-rule ubiquitylation system and, optionally, a proteasome inhibitor; and
- b) incubating said mixture to allow production of said complex.

6. (original) The method of claim 5, further comprising:

- c) isolating said complex.

7. (original) The method of claim 6, wherein said isolating is done by binding to an antibody specific to a poly-ubiquitin chain.

8. (original) The method of claim 6, wherein said isolating is done by binding to an antibody specific for said protein.

Claim 9 (canceled)

10. (previously presented) An isolated activated fragment of a protein, said fragment having an exposed N-degron, wherein said protein has a hidden N-degron and is selected from the group consisting of aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin 3, HMGN3, HSPC144 and CDC6 and fragments and derivatives thereof.

Claim 11 (canceled)

12. (previously presented) The activated fragment of claim 10, wherein said activated fragment is immobilized on a support and/or linked to a label.

Claims 13-14 (canceled)

15. (previously presented) A method of producing an activated fragment of a protein having an exposed N-degron, wherein said protein is selected from the group consisting of aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin 3, HMGN3, HSPC144 and CDC6 and fragments and derivatives thereof, comprising:

- a) forming a mixture comprising said protein and a protease which cleaves said protein to form said activated fragment; and
- b) incubating said mixture to allow production of said activated fragment.

16. (previously presented) The method of claim 15, further comprising:

- c) isolating said activated fragment.

17. (currently amended) ~~An assay~~ A composition comprising ~~[[an]]~~ a complex comprised of at least one ubiquitin and a protein, wherein said protein is selected from the group consisting of aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin-3, HMGN3, HSPC144 and CDC6 and fragments and derivatives thereof, wherein said fragments and derivatives thereof comprise polypeptides of at least 10 amino acids having at least 60% sequence similarity to sequences within their corresponding proteins; said complex is formed via N-end rule ubiquitylation; and said ubiquitin and/or said protein complex is immobilized on a support and/or linked to a label.

Claims 18-34 (canceled)

35. (previously presented) A method for identifying one or more active compounds that modulate N-end rule dependent ubiquitylation of a protein selected from the group comprising aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin 3, HMGN3, HSPC144 and CDC6, comprising:

- a) forming a mixture comprising said protein or a fragment or derivative thereof, an N-rule ubiquitylation system, one or more candidate compounds and, optionally, a proteosome system;
- b) measuring N-end rule ubiquitylation and/or proteosome-mediated degradation of said protein or a fragment or derivative thereof; and
- c) identifying one or more compounds that modulate the rate of ubiquitylation or degradation.

36. (previously presented) The method of claim 35, wherein said protein or a fragment or derivative thereof includes a pro-N-degron and said mixture of step a) further includes a protease which exposes said N-degron.

37. (previously presented) The method of claim 35, wherein said protein or a fragment or derivative thereof is an activated fragment of said protein having an exposed N-degron.

38. (previously presented) The method of claim 35, wherein said active compound modulates activity of an E1 ligase, E2 ligase, E3 ligase, a protease that exposes said N-degron, or a combination thereof.

39. (previously presented) The method of claim 35, wherein said active compound modulates activity of an E1 ligase, E2 ligase and/or E3 ligase, or a combination thereof.

40. (original) A method for determining the mechanism of a compound that affects N-end rule ubiquitylation, comprising:

- a) performing the identifying method of claim 36;
- b) repeating said identifying method, except that said mixture further comprises an inhibitor of N-end rule ubiquitylation or said protein is replaced with a pre-activated fragment of said protein having said exposed N-degron; and
- c) determining whether said compound is specific for said protease, and/or said N-end rule ubiquitylation system.

41. (original) A method for determining the mechanism of a compound that affects N-end rule ubiquitylation, comprising:

- a) performing the identifying method of claim 35;
- b) repeating said identifying method, except that said mixture further comprises an additional modulator of Type I, Type II and/or Type III N-end rule ubiquitylation; and
- c) determining where said compound affects Type I, Type II and/or Type III N-end rule ubiquitylation.

42. (original) A method of making a pharmaceutical formulation containing one or more active compounds which modulate N-end rule ubiquitylation of a protein selected from

the group consisting of aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin 3, HMGN3, HSPC144 and CDC6, comprising:

- a) forming a mixture comprising said protein, or an activated fragment of said protein having an exposed N-degron, an N-rule ubiquitylation system, one or more candidate compounds and, optionally, a proteosome system;
- b) detecting N-end rule ubiquitylation and/or proteosome-mediated degradation of said protein;
- c) identifying one or more active compounds from said one or more candidate compounds; and
- d) incorporating at least one of said one or more active compounds into a pharmaceutical formulation comprising said at least one active compound and suitable carrier.

43. (previously presented) The method of claim 42, wherein said one or more active compounds are inhibitors of N-end rule ubiquitylation.

44. (previously presented) The method of claim 42, wherein said one or more active compounds are promoters of N-end rule ubiquitylation.

45. (previously presented) The method of claim 42, wherein said one or more active compounds are naturally occurring.

46. (previously presented) The method of claim 42, wherein said one or more candidate compounds are selected from a compound library.

47. (previously presented) The method of claim 42, wherein said one or more candidate compounds are selected from a compound library of FDA approved drugs.

Claims 48-54 (canceled)

55. (original) A library of N-end rule ubiquitylation substrates including at least two proteins, or fragments or derivatives thereof, selected from the group consisting of aprataxin, tau, SLP, HMG17, PinX1, CIR, Cullin 3, HMGN3, HSPC144 and CDC6.

Claim 56 (canceled)

57. (new) An isolated complex comprising at least one ubiquitin or a derivative thereof, and a protein; wherein said protein is selected from the group consisting of tau, Cullin 3, CDC6 and fragments and derivatives thereof, wherein said fragments and derivatives thereof comprise polypeptides of at least 10 amino acids having at least 60% sequence similarity to sequences within their corresponding proteins; and said complex is formed via N-end rule ubiquitylation.

58. (new) The complex of claim 57, wherein said complex is immobilized on a support and/or linked to a label.

59. (new) A composition comprising a complex comprised of at least one ubiquitin and a protein, wherein said protein is selected from the group consisting of tau, Cullin 3, CDC6 and fragments and derivatives thereof, wherein said fragments and derivatives thereof comprise polypeptides of at least 10 amino acids having at least 60% sequence similarity to sequences within their corresponding proteins; said complex is formed via N-end rule ubiquitylation; and said complex is immobilized on a support and/or linked to a label.

60. (new) The complex of claim 3, wherein said fragment is an activated fragment of a protein, said fragment having an exposed N-degron.

61. (new) The complex of claim 60, wherein said activated fragment is immobilized on a support and/or linked to a label.

62. (new) The complex of claim 57, wherein said fragment is an activated fragment of a protein, said fragment having an exposed N-degron.

63. (new) The complex of claim 62, wherein said activated fragment is immobilized on a support and/or linked to a label.